Mondovits B, Vermylen C, Brichard B, Cornu G
Service d'hématologie pédiatrique, cliniques universitaires Saint-Luc, avenue Hippocrate 10, 1200 Bruxelles, Belgique.
Arch Pediatr. 2001 Aug;8(8):801-6. doi: 10.1016/s0929-693x(01)00538-3.
Follow-up of patients with Fanconi's anemia treated in our unit and review of the literature concerning bone marrow transplantation in Fanconi's anemia.
Ten patients were followed in our unit for 20 years. We summarize their clinical features, treatment and clinical course.
Among the ten patients, seven received allogeneic marrow transplantation. Only two patients are still alive. Two transplanted patients died from complications shortly after the transplantation. Three other patients died later after the transplantation, two of them from oropharyngeal carcinomas.
The 5-year survival is about 70% in the transplantation with an HLA-identical sibling donor; it is only about 30% if the donor is an HLA-matched unrelated or mismatched related patient. Furthermore, retrospective studies have shown that the long-term outcome of carcinoma is a major complication after the transplantation.
Our series of patients with Fanconi's anemia reflects fairly faithfully the complications encountered in this disease. Although the improvement of the graft technique may decrease the rate of death due to transplantation, the long-term development of solid tumors remains a problem for which no solution has been suggested up to now.
对在我院接受治疗的范科尼贫血患者进行随访,并回顾有关范科尼贫血骨髓移植的文献。
10例患者在我院接受了20年的随访。我们总结了他们的临床特征、治疗方法及临床病程。
10例患者中,7例接受了异基因骨髓移植。仅2例患者仍存活。2例移植患者在移植后不久死于并发症。另外3例患者在移植后较晚时间死亡,其中2例死于口咽癌。
在接受人类白细胞抗原(HLA)相同的同胞供者移植的患者中,5年生存率约为70%;如果供者是HLA匹配的无关供者或HLA不匹配的亲属供者,5年生存率仅约为30%。此外,回顾性研究表明,癌症是移植后的主要远期并发症。
我们的范科尼贫血患者系列相当忠实地反映了该病所遇到的并发症。尽管移植技术的改进可能会降低移植相关死亡率,但实体瘤的远期发生仍是一个问题,目前尚无解决办法。